Brief: Calidi Biotherapeutics Eliminates Chief Legal Officer Position - SEC Filing
19/09/2025 22:23
Sept 19 (Reuters) - SEC Filing: CALIDI BIOTHERAPEUTICS INC - ELIMINATES CHIEF LEGAL OFFICER POSITION - SEC FILING Source text: [ID:n0001493152-25-014293] Further company coverage: CLDI.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Calidi Biotherapeutics
See all newsBrief: Calidi Biotherapeutics Announces Strategic Partnership With Transferai
Brief: Calidi Biotherapeutics Announces Partnership With Avance Clinical To Facilitate Australian Regulatory Approval
Brief: Calidi Biotherapeutics Announces Pricing Of $5.2 Million Underwritten Public Offering
Brief: Calidi Biotherapeutics Eliminates Chief Legal Officer Position - SEC Filing
Brief: Calidi Biotherapeutics Receives FDA Fast Track Designation For Cld-201 (Supernova), A First-In-Class Stem-Cell Loaded Viral Therapy For The Treatment Of Patients With Soft Tissue Sarcoma